## Performance in Delivering Clinical Trials - Q1 2020/21

<b>Research Ethics</b>	Integrated	Name of Trial	Target Number Of	Minimum	Maximum	Target Date To	Date agreed	Total Number	<b>Total Number</b>	Date that the trial closed to	Reason For Closure Of
Committee	Research		Patients Agreed?	Number Of	Number Of	Recruit Patients	to recruit	Of patients	Of Study	recruitment	Trial
Reference	Application			Patients	Patients	Agreed?	target	<b>Recruited at the</b>	Participants		
Number	System			Agreed	Agreed		number of	agreed date	Recruited		
	Number						participants				
17/EE/0460	231790	Algorithmic Protamine Dosing for Reversal of Heparin after Cardiopulm	<ul> <li>b) Number agreed</li> </ul>	120	120	<ul><li>b) Date agreed</li></ul>	01/06/2020	179	179	31/08/2019	Withdrawn By Sponsor
8/YH/0330	236317	A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre	<ul> <li>b) Number agreed</li> </ul>	22	22	<ul> <li>b) Date agreed</li> </ul>	28/03/2020	7	7	12/05/2020	Recruitment Finished
18/LO/1258	248312	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the	Boliji Oskanyn baned Sig feteyd of I	BG00011 in Pa <b>f</b> i	ents With Idioa	att)hDcaRelagoeady Fibro	sis01/09/2020	1	1	22/08/2019	Withdrawn By Sponsor
19/LO/0576	253302	A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Eva	c) Range agreed	4	24	<ul> <li>b) Date agreed</li> </ul>	31/03/2020	0	0	09/06/2020	Withdrawn By Sponsor
19/LO/0343	255538	The PRECISE Protocol: Prospective Randomized Trial of the Optimal Eva	c) Range agreed	20	30	<ul> <li>b) Date agreed</li> </ul>	01/06/2020	3	3	01/06/2020	Withdrawn By Sponsor